VTGN — Vistagen Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $7.97m
- -$23.76m
- $1.27m
Annual cashflow statement for Vistagen Therapeutics, fiscal year end - March 31st, USD millions except per share, conversion factor applied.
2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | 2026 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -47.8 | -59.2 | -29.4 | -51.4 | -69.7 |
| Depreciation | |||||
| Non-Cash Items | 4.27 | 3.82 | 2.63 | 4.41 | 3.99 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -1.92 | 5.59 | 0.793 | 4.76 | -0.938 |
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -45.3 | -49.7 | -25.8 | -42.1 | -66.4 |
| Capital Expenditures | -0.2 | -0.212 | -0.061 | -0.191 | -0.151 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | -0.528 | 0 | -13 | -0.726 |
| Acquisition of Business | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -0.2 | -0.74 | -0.061 | -13.1 | -0.877 |
| Financing Cash Flow Items | 4.04 | -0.174 | — | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 10.5 | -1.04 | 128 | 3.21 | 31 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -35 | -51.5 | 103 | -52 | -36.3 |